Comparative Pharmacology
Head-to-head clinical analysis: PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER versus PEPCID RPD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER versus PEPCID RPD.
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER vs PEPCID RPD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive histamine H2-receptor antagonist; inhibits gastric acid secretion by blocking H2 receptors on parietal cells.
Competitive antagonist of histamine H2 receptors in gastric parietal cells, inhibiting gastric acid secretion (basal and stimulated).
20 mg intravenously every 12 hours; or 40 mg intravenously once daily. For Zollinger-Ellison syndrome, initial dose 20 mg intravenously every 6 hours; adjust based on acid output.
20 mg orally 1-2 times daily for GERD; 40 mg orally once daily for duodenal ulcer or erosive esophagitis. Max 40 mg/day.
None Documented
None Documented
2.5–3.5 hours in normal renal function; prolonged to 6–8 hours in moderate renal impairment (CrCl <50 mL/min) and up to 20 hours in severe renal failure (CrCl <10 mL/min)
Terminal elimination half-life 2.5-3.5 hours (prolonged to ~12-20 hours in renal impairment; CrCl <10 mL/min).
Renal (65–70% unchanged via tubular secretion and glomerular filtration); biliary/fecal (minor, <10%)
Renal (25-30% as unchanged drug); biliary/fecal (approximately 70% as metabolites); hepatic metabolism to famotidine S-oxide.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist